Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LIFESTREAM HEALTH CENTER

NPI: 1881728996 · BOWIE, MD 20716 · Specialist · NPI assigned 03/14/2007

$1.79M
Total Medicaid Paid
25,068
Total Claims
20,394
Beneficiaries
8
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMERRITT, SARAH (OWNER)
NPI Enumeration Date03/14/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 904 $67K
2019 2,195 $146K
2020 4,703 $303K
2021 3,992 $265K
2022 4,491 $300K
2023 4,213 $312K
2024 4,570 $393K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 16,403 13,537 $1.41M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 7,268 5,581 $300K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 353 337 $31K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 521 446 $29K
80305 436 406 $4K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 31 31 $4K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 26 26 $4K
96127 30 30 $136.59